-
New Phase I Trial Explores Promising Immunotherapy Combination for Urothelial Cancer
A new Phase I clinical trial is investigating whether combining durvalumab with the HDAC inhibitor belinostat can enhance the immune system’s ability to fight advanced urothelial cancer.
-
FDA Advisory Panel Signals Support for Broader BPC-157 Access
An FDA advisory panel has reportedly backed expanded access to BPC-157, a move that could open the door to more regulated availability of this closely watched peptide. The news sent shares of telehealth company Hims & Hers higher.
-
FDA Grants Tentative Approval for Generic Semaglutide
The FDA has given tentative approval to a generic version of semaglutide, signaling a potential path toward more affordable access to this widely used medication in the future.
-
FDA Approves MIMRYLO (rusfertide), a Novel Hepcidin Mimetic Peptide for Polycythemia Vera
Protagonist Therapeutics announced that the U.S. FDA has approved MIMRYLO (rusfertide), a first-in-class hepcidin mimetic peptide, offering a new treatment option for patients with polycythemia vera.
-
FDA-Approved Peptide Therapies Offer New Options for Weight Management
The FDA has approved peptide-based medications for weight loss, giving patients and healthcare providers additional evidence-based tools to address obesity and related health concerns.
-
Scientists Gather to Advance Oral Peptide Delivery at Fourth CRS Workshop
Leading researchers convened for the fourth Controlled Release Society workshop dedicated to oral peptide administration, highlighting ongoing progress toward needle-free peptide therapies.
-
FDA-Approved Peptide Therapies Offer New Options for Weight Management
The FDA has approved peptide-based medications for chronic weight management, giving patients and physicians additional evidence-based tools to address obesity.
-
New Clinical Trial Launches to Compare Innovative Peptide-Drug Conjugate Against Standard Chemotherapy for Lung Cancer
A new clinical trial, IZABRIGHT-Lung01, is now underway to evaluate izalontamab brengitecan, a novel antibody-drug conjugate, as a potential treatment option for patients with EGFR-mutated non-small cell lung cancer whose disease has progressed after targeted therapy.
-
New Clinical Trial Launches to Explore Investigational Peptide-Based Therapy ABBV-901 for Ovarian Cancer
A new multi-part global clinical trial is underway to evaluate ABBV-901, an investigational antibody-drug conjugate therapy, alone and in combination with established anticancer treatments for ovarian cancer patients.
-
New Pilot Trial to Explore Oral Vancomycin for Ulcerative Colitis Patients with Liver Condition PSC
A new feasibility trial will investigate whether oral vancomycin, a glycopeptide antibiotic, can safely ease ulcerative colitis symptoms in patients who also have primary sclerosing cholangitis. The study aims to pave the way for larger future research.